BioCentury on BioBusiness,
Finance
Table: 4Q approvals
Back to the parent article
Published on
Monday, January 7, 2013
|
Selected fourth quarter
product approvals.
|
|
Company
|
Approval
|
|
|
|
|
Aegerion
Pharmaceuticals Inc. (NASDAQ:AEGR)
|
FDA approves Juxtapid lomitapide to treat homozygous
familial hypercholesterolemia (hoFH)
|
|
Alexza
Pharmaceuticals Inc. (NASDAQ:ALXA)
|
FDA
approves Adasuve Staccato loxapine to treat acute agitation in adults with
schizophrenia or bipolar disorder
|
|
Ariad
Pharmaceuticals Inc. (NASDAQ:ARIA)
|
FDA
approves Iclusig ponatinib to treat chronic myelogenous leukemia (CML)
and
|
|
|
Philadelphia
chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) that is
resistant to or intolerant of prior treatment with tyrosine kinase inhibitors
|
|
AstraZeneca
plc (LSE:AZN; NYSE:AZN)/Bristol-Myers
Squibb Co. (NYSE:BMY)
|
EC
approves Forxiga dapagliflozin to treat Type II diabetes
|
|
Bayer
AG (Xetra:BAYN)/
|
EC
approves Xarelto rivaroxaban to treat pulmonary embolism (PE) and to prevent
|
|
Johnson
& Johnson (NYSE:JNJ)
|
recurrent
deep vein thrombosis (DVT) and PE; FDA approves Xarelto to treat DVT or PE,
and to reduce the risk of recurrent DVT and PE
|
134
words displayed of
618
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]